Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159458 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00159458 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 7 participants.
The verdict
NCT00159458, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the combination of gemcitabine and oxaliplatin chemotherapy will be effective in reducing or eliminating the tumor(s) in patients with recurrent or metastatic breast cancer. Gemcitabine is a chemotherapy drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic and lung cancer; oxaliplatin is a chemotherapy drug that is approved by the FDA for the treatment of colon cancer. Neither gemcitabine nor oxaliplatin are approved for the treatment of breast cancer. However, both drugs have been shown to decrease the size of breast cancer tumors.
Interventions
- DRUG Gemcitabine and oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00159458
The ClinicalTrials.gov registry entry for NCT00159458 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine and oxaliplatin is the first listed.
NCT00159458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00159458 about?
NCT00159458 is a clinical study titled "Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer". The purpose of this study is to find out if the combination of gemcitabine and oxaliplatin chemotherapy will be effective in reducing or eliminating the tumor(s) in patients with recurrent or metastatic breast cancer. Gemcitabine is a chemotherapy drug approved by the U.S. Food and Drug Administrat...
What is the current status of trial NCT00159458?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2003-07. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00159458?
The interventions under investigation include: Gemcitabine and oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00159458?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.